TABLE 30Incremental cost-effectiveness ratio (ICER) for imatinib-resistant patients aged 57 years

InterventionCosts (£)LYs (£)QALYs (£)ICER (LYG) (£)ICER (QALY) (£)
HDI146,2345.534.28
Nilotinib139,2165.804.51−26,006−30,513
SCT/HU80,9334.213.1836,74844,028

HDI, high-dose imatinib; HU, hydroxycarbamide; SCT, stem cell transplantation.

Exploratory analysis is shown in italic text.

From: 4, Economic analysis

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.